Withdrawal from 1-week oral administration of the benzodiazepine, flurazepam (FZP) is associated with increased a-amino-3-hydroxy-5-methylisoxasole-4propionic acid (AMPA) receptor (AMPAR) miniature excitatory postsynaptic currents (mEPSCs) but reduction of N-methyl-D-aspartic acid (NMDA) receptor (NMDAR)evoked (e)EPSCs in hippocampal CA1 neurons. A positive correlation was observed between increased AMPARmediated mEPSC amplitude and anxiety-like behavior in 1-day FZP-withdrawn rats. These effects were disrupted by systemic AMPAR antagonist administration (GYKI-52466, 0.5 mg/kg, intraperitoneal) at withdrawal onset, strengthening the hypothesis that CA1 neuron AMPARmediated hyperexcitability is a central component of a functional anatomic circuit associated with the expression of withdrawal anxiety. Abolition of AMPAR current upregulation in 2-day FZP withdrawn rats by GYKI-52466 injection also reversed the reduction in NMDAR-mediated eEPSC amplitude in CA1 neurons from the same rats, suggesting that downregulation of NMDAR function may serve a protective, negative-feedback role to prevent AMPAR-mediated neuronal overexcitation. NMDAR antagonist administration (MK-801, 0.25 mg/kg intraperitoneally) had no effect on modifying increased glutamatergic strength or on withdrawal anxiety, whereas injection of an L-type voltage-gated calcium channel antagonist, nimodipine (10 mg/kg, intraperitoneally) averted AMPAR current enhancement and anxiety-like behavior, suggesting that these manifestations may be initiated by a voltage-gated calcium channel-dependent signal transduction pathway. An evidence-based model of likely cellular mechanisms in the hippocampus contributing to benzodiazepine withdrawal anxiety was proposed implicating regulation of multiple CA1 neuron ion channels.
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Introduction
Benzodiazepines, a group of positive allosteric modulators of g-aminobutyric acid type A receptors (GABA A Rs), are widely prescribed for the treatment of anxiety and insomnia and are frequently used by polydrug abusers. After withdrawal from long-term use, symptoms such as anxiety, agitation, sleep disturbances and in some cases delirium or seizures may appear, which can lead to physical dependence and benzodiazepine misuse or further abuse (Griffiths and Johnson, 2005 ).
An extensive literature suggests that different neural mechanisms mediated by distinct neural pathways might underlie the different components of the benzodiazepine withdrawal syndrome (Allison et al., 1999; Podhorna, 2002; Allison and Pratt, 2003; Millan, 2003; Ganouni et al., 2004; Van Sickle et al., 2004) . The hippocampus is an important component in anxiety expression (Millan, 2003) and various CA1 pyramidal neuron membrane receptors are suggested to be involved in anxiogenic behavior observed in the elevated plus-maze test in rats (Degroot et al., 2001; Izzo et al., 2001; Lamprea et al., 2003; Van Sickle et al., 2004) . Excitatory, glutamatergic neuronal circuits have been implicated in mediating withdrawal symptoms associated with a variety of drugs of abuse (Molleman and Little, 1995; Stephens, 1995; Little, 1999; Jackson et al., 2000; Jang et al., 2000; Vekovischeva et al., 2001; Rajadhyksha and Kosofsky, 2005; Zhong et al., 2006) . The findings that pharmacologic antagonism of a-amino-3-hydroxy-5-methylisoxasole-4-propionic acid receptors (AMPARs) and N-methyl-D-aspartate receptors (NMDARs) differentially modify behavioral manifestations of benzodiazepine withdrawal (Steppuhn and Turski, cortex are regulated after withdrawal from benzodiazepines (Allison et al., 1999; Izzo et al., 2001; suggest that glutamatergic receptors may also play important roles in mediating benzodiazepine withdrawal signs.
Activity-dependent increases in AMPAR synaptic function are primarily the consequence of an intracellular calciumdependent biochemical cascade and involve a variety of possible structural and/or functional changes in synaptic AMPARs (Malenka, 2003; Boehm and Malinow, 2005) . NMDAR-dependent calcium signaling has been shown to be a primary mediator of enhanced AMPAR function associated with both Hebbian and homeostatic plasticity phenomena (Malenka, 2003; Perez-Otano and Ehlers, 2005) . Another important calcium source, L-type voltagegated calcium channels (L-VGCCs), however, has also been implicated in activity-dependent synaptic plasticity (Morgan and Teyler, 1999; Rajadhyksha and Kosofsky, 2005) . Moreover, L-type VGCCs have been shown to be involved in mediating withdrawal signs to a variety of central nervous system (CNS) depressants (Whittington and Little, 1993; Pourmotabbed et al., 1998; Rabbani and Little, 1999; Podhorna, 2002; Ganouni et al., 2004) . Whether NMDAR-mediated or VGCC-mediated calcium signaling contributes to the regulation of AMPAR synaptic plasticity during flurazepam (FZP) withdrawal is unknown.
Previous studies in our laboratory were focused on the functional regulation of glutamate receptors on hippocampal CA1 neurons after prolonged benzodiazepine administration. A transient enhancement of AMPARmediated miniature excitatory postsynaptic currents (mEPSCs) and a reduction in NMDAR-mediated evoked (e)EPSCs were observed (Van Sickle et al., 2004) in 2-day FZP-withdrawn rats. In this investigation, we first evaluated the relationship between increased CA1 neuron AMPAR function and anxiety-like behavior in rats by pharmacological antagonism of glutamate receptor activity at the onset of withdrawal. Next, systemic AMPA antagonist injections in other groups of rats were used to assess the role of AMPA plasticity in mediating subsequent effects on CA1 neuron NMDAR function. Furthermore, by means of pharmacological antagonism of either NMDAR or L-VGCC activity, the possible Ca 2+mediated mechanism underlying enhanced AMPAR activity during benzodiazepine withdrawal was explored. Finally, to serve as the foundation for more mechanistic studies, a model of the cellular mechanisms underlying benzodiazepine withdrawal anxiety was proposed based on the present findings, and on past evidence from our laboratory and others.
Methods
Experimental protocols involving the use of vertebrate animals were approved by the University of Toledo College of Medicine (formerly the Medical University of Ohio), Institutional Animal Care and Use Committee and conformed to National Institutes of Health ethical guidelines.
Drug treatments
Chronic flurazepam administration FZP treatment in rats was as previously described (Van Sickle et al., 2004) . In short, following a 2-4 day adaptation period when rats were offered only a 0.02% saccharin vehicle, male Sprague-Dawley rats (initial age 22-25 days postnatal, Harlan, Indianapolis, Indiana, USA) were offered FZP (flurazepam dihydrochloride, pH 5.8) for 1 week in saccharin solution as their only source of drinking water. The concentration of FZP was adjusted daily according to each rat's body weight and fluid consumption (100 mg/kg Â3 days and 150 mg/kg Â4 days) appropriate to FZP's relative potency, oral bioavailability and biotransformation resulting in benzodiazepine brain levels equivalent to other common benzodiazepine chronic treatments (Gallager et al., 1985; Lau et al., 1987; Xie and Tietz, 1992) . Only rats that consumed a criterion dose of an average of more than 120 mg/kg/day were accepted for study. Saccharin water was again provided during the 2-day withdrawal period. Unlike in humans, residual FZP and metabolites rapidly decline over the first 24 h after drug removal and are no longer detectable in hippocampus in 2-day FZP-withdrawn rats (Xie and Tietz, 1992) . Pair-handled control rats receive saccharin water for the same length of time. Rats were euthanized for hippocampal slice preparation on postnatal day 35-40.
Systemic antagonist injection
Three groups of control and FZP-treated rats were given a single intraperitoneal injection of one of three different ion channel antagonists, optimal doses determined in previous studies (Van Sickle et al., 2004) . First, the selective, competitive AMPAR antagonist, GYKI-52466 (0.5 mg/kg, intraperitoneally) or 1% Tween-20 vehicle (0.5 ml/kg) was injected immediately at the end of 1 week of FZP treatment, 24 h (1-day withdrawn) before behavioral testing and 24 or 48 h (1 and 2-day withdrawn groups) before tissue preparation for electrophysiological recording. Among the range of doses tested, this dose was previously shown to reverse the increased AMPAR mEPSC amplitude without anxiogenic effects in rats (Van Sickle et al., 2004) . In the second group, the noncompetitive NMDAR antagonist, MK-801 (0.25 mg/kg, intraperitoneally) or saline vehicle (1 ml/kg) were given at the end of 1 week FZP treatment and 24 h before both behavioral testing and hippocampal slice preparation. This dose was previously shown to reverse downregulation of NMDAR function in 2-day FZP-withdrawn rats 1 day after systemic injection without adverse locomotor effects (Van Sickle et al., 2004) . The third group was preinjected with the L-VGCC antagonist, nimodipine (10 mg/kg, intraperitoneally) or the vehicle 0.5% Tween 80 (2 ml/kg) immediately after ending 1-week FZP treatment and 24 h before behavioral testing and slice preparation. This dose of nimodipine has minimal effect on locomotion, does not produce ataxia, has no effect on seizure threshold, yet reverses behavioral signs of ethanol dependence (Watson and Little, 2002) .
Behavioral testing Elevated plus-maze test
The elevated plus-maze, which represents unconditioned responses to a potentially dangerous environment, is a widely used measure of anxiety and the anxiolytic effects of drugs (Rodgers and Dalvi, 1997) . The plus-maze consisted of two opposite open arms, 50 Â 10 cm, crossed with two closed arms of the same dimensions, with walls 40 cm high. The arms were connected with a central square, 10 Â 10 cm. The plus-maze was elevated 50 cm above the floor in a dimly illuminated, 144-sq. ft. room. As described previously (Van Sickle et al., 2004) , all rats were naive to the plus-maze, and were tested only once between 10.00 and 10.30 h before being killed for hippocampal slice preparation either the same or the following day as described below. The test was initiated by placing a rat in the central square facing an open arm. The number of arm entries and the time spent in open and closed arms were record for 5 min by an observer in the same room. An arm entry was scored when all four limbs were on the arm. The maze was cleaned with 100% ethanol and then with distilled water before and after each rat was tested.
Electrophysiology

Hippocampal slice preparation
Hippocampal slices (400 mm) were prepared from rats as previously described (Van Sickle et al., 2004) . Briefly, transverse dorsal hippocampal slices were cut on a vibratome (Ted Pella, Redding, California, USA) in icecold, pregassed (95% O 2 /5% CO 2 ) artificial cerebrospinal fluid (ACSF) containing (in mmol/l): NaCl, 120; KCl, 2.5; CaCl 2 , 0.5; MgSO 4 , 7.0; NaH 2 PO 4 , 1.2; NaHCO 3 , 2; D-glucose, 20; ascorbate, 1.3, pH 7.4. Slices were maintained at room temperature (RT) for 15 min in gassed, low-calcium, high-magnesium ACSF, then transferred to normal ACSF containing (in mmol/l): NaCl, 119; KCl, 2.5; CaCl 2 , 1.8; MgSO 4 , 1.3; NaH 2 PO 4 , 1.25; NaHCO 3 , 26; D-glucose, 10; pH 7.4. Slices were maintained at RT for Z 1 h in ACSF. During recording, slices were superfused at a rate of 2.5 ml/min with gassed ACSF at RT. AMPAR-mediated miniature excitatory postsynaptic current recording AMPAR-mediated mEPSCs were isolated from CA1 neurons in ACSF plus 1 mmol/l tetrodotoxin, 50 mmol/l picrotoxin and 25 mmol/l CGP-35348 using whole-cell voltage-clamp techniques as previously described . Patch pipettes (3-6 MO) were filled with internal solution containing (in mmol/l): Csmethanesulfonate, 132.5; CsCl, 17.5; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 10; ethylene glycol tetraacetic acid, 0.2; NaCl, 8; Mg-ATP, 2; Na 3 -GTP, 0.3; lidocaine N-ethyl bromide quaternary salt (QX-314), 2; pH 7.2 adjusted with CsOH. Resting membrane potential (RMP) was measured immediately upon cell break-in. Neurons were voltage-clamped (V H = -80 mV) in continuous mode (cSEVC) using an Axoclamp 2A amplifier (Axon Instruments, Union City, California, USA). Current output was low-pass filtered (10 kHz), DC-offset, amplified 10 000-fold and continuously monitored on-line (PClamp 8.0, Axon). The digitized signal (Digidata 1200A, Axon) was stored on disk for later offline analysis. Cells in which the holding current changed by more than 20%, or the seal degraded, were abandoned. mEPSC activity was recorded for 5 min and analyzed with MiniAnalysis software (Synaptosoft Inc., Leonia, New Jersey, USA). Peak mEPSC amplitude was measured from baseline. Decay kinetics and mEPSC amplitude were estimated using a single exponential function: [y(t) = a*exp( -t/t)]. Whole-cell data were compared by repeated measures analysis of variance with post-hoc analysis by the method of Scheffé (P < 0.05). AMPAmediated mEPSCs were abolished in the presence of 10 mmol/l 6,7-dinitroquinoxaline-2,3-done (DNQX) .
Stimulus-evoked, N-methyl-D-aspartic acid receptormediated excitatory postsynaptic current recording NMDAR-mediated, stimulus-evoked (e)EPSCs were recorded from CA1 neurons in in-vitro hippocampal slices by stimulation of the Schaffer collateral pathway in the presence of 10 mmol/l DNQX, 10 mmol/l glycine, 25 mmol/l CGP-35348 and 50 mmol/l picrotoxin using whole-cell voltage-clamp techniques as described previously . Patch pipettes (5-9 MO) were filled with internal solution containing (in mmol/l): Cs-methanesulfonate, 132.5; CsCl, 17.5; HEPES, 10; ethylene glycol tetraacetic acid, 0.2; NaCl, 8; Mg-ATP, 2; Na 3 -GTP, 0.3; QX-314, 2; pH 7.2 adjusted with CsOH. After establishing input-output relationships, NMDAR-mediated EPSCs were elicited with a tungsten, bipolar stimulating electrode at a stimulus intensity half-maximal for the EPSC. Neurons were voltage-clamped from -80 to + 40 mV in continuous mode (cSEVC) using an Axoclamp 2A amplifier (Axon) monitored and digitized as described above. Currentvoltage (I-V) curves were compared by repeated measures analysis of variance followed by post-hoc analysis by the method of Scheffé (P < 0.05). In preliminary experiments, NMDA-mediated currents were abolished in the presence of 50 mmol/l DL-2-amino-5-phosphonovaleric acid (APV) (Van Sickle et al., 2002).
Nimodipine concentration-response effects on miniature excitatory postsynaptic currents
To determine whether nimodipine had direct effects on AMPAR-mediated mEPSCs, nimodipine (0.1-100 mmol/l) was superfused onto hippocampal slices during mEPSC recording. After recording baseline mEPSC activity for 5 min, nimodipine or vehicle (0.0001-0.1% dimethyl sulfoxide in water) was added to the superfusate in increasing concentrations for 10 min each. mEPSC amplitude and kinetics were analyzed using the final 5 min recording period at each concentration.
Drug solutions
Drugs used for superfusion during whole-cell recording were dissolved at 100 times their final concentration and added to the superfusate with a syringe pump (Razel, World Precision Instruments, Inc., Sarasota, Florida, USA) at a rate of 25-75 ml/min to achieve their final concentrations. GYKI-52466 for systemic injection was suspended in 1% Tween-20 solution. MK-801 was dissolved in the saline vehicle. For in-vivo injection, nimodipine was dissolved in 0.5% Tween-80 solution and kept in a light-tight vial. For in-vitro perfusion, nimodipine was dissolved in dimethyl sulfoxide to make a 10 mmol/l stock solution diluted to the final concentration as needed (from 0.1 to 100 mmol/l). All other drugs were dissolved in dH 2 O. DNQX, QX-314, MK-801, picrotoxin, FZP dihydrochloride, nimodipine and GYKI-52466 are all from Sigma-Aldrich Chemical Co. (St Louis, Missouri, USA). Tetrodotoxin was obtained from Alamone Laboratories (Jerusalem, Israel). CGP 35348 was purchased from Tocris Bioscience (Ellisville, Missouri, USA).
Results
Positive correlation between increased AMPAR function and flurazepam withdrawal anxiety reversed by systemic GYKI-52466 injection
Previously we reported that in 1-day FZP-withdrawn rats, anxiety-like behavior is observed in the elevated plus-maze test concomitant with an increase in AMPAR-mediated mEPSC amplitude in hippocampal CA1 neurons, effects prevented by systemic injection of the noncompetitive AMPAR antagonist GYKI-52466 (Van Sickle et al., 2004) . Evidence of a correlation between enhanced AMPAR function and benzodiazepine withdrawal anxiety, however, was not sought. Therefore, we first examined whether there is a positive correlation between AMPAR-mediated mEPSC amplitude and benzodiazepine withdrawal anxiety score and, once established, whether normalizing mEPSC amplitude via prior systemic antagonist injection could disrupt the correlation.
Control and FZP-withdrawn rats were injected with vehicle (1% Tween-20) or GYKI-52466 (0.5 mg/kg) immediately after the removal of FZP from the drinking water. Rats were then tested 1 day later in the elevated plus-maze before hippocampal slice preparation for mEPSC recording. Fig. 1a shows representative inward mEPSCs recorded in CA1 neurons (V H = -80 mV) from control or 1-day FZP-withdrawn rats 24 h after vehicle or GYKI-52466 injection. AMPA current amplitudes increased significantly (30%) in neurons from 1 day FZPwithdrawn rats as reported previously (15-30%, Van Sickle et al., 2004) and there was a significant positive correlation (R 2 = 0.66, P < 0.001) between AMPARmediated mEPSC amplitude and the percentage openarm time (Fig. 1b) , indicating a strong correlation between increased CA1 neuron AMPAR function and FZP withdrawal anxiety. A positive correlation was also observed when control data from all vehicle-injected rats (n = 25 cells), used to evaluate AMPAR, NMDAR and L-VGCC antagonist effects, were pooled (R 2 = 0.25, P = 0.01, Figs 1b, 3c and 4c). Prior systemic injection of GYKI-5246 abolished this correlation ( Fig. 1c , R 2 = 0.03, NS). Together, these findings further support a role for upregulation of CA1 neuron AMPAR function and increased hippocampal output activity in FZP withdrawal anxiety.
Antagonism of AMPAR activation at withdrawal onset prevented both upregulation of AMPAR function and downregulation of N-methyl-D-aspartic acid receptor function in 2-day flurazepam-withdrawn rats
We postulated that the increase in AMPAR-mediated current during FZP withdrawal initiates downregulation of NMDAR-mediated channel activity to offset the AMPAR-mediated expression of withdrawal anxiety, suggesting a compensatory role for downregulation of NMDAR-mediated function secondary to the AMPARmediated CA1 neuron hyperexcitability observed . To evaluate this hypothesis, additional groups of rats were injected with GYKI-52466 immediately after FZP withdrawal and tested 1 day later in the plus-maze. Hippocampal slice preparation was performed the following day and both AMPAR-mediated mEPSCs and NMDAR-mediated eEPSCs were then evaluated in slices from the same, then 2-day FZPwithdrawn rats.
As previously reported, 1-day FZP-withdrawn rats injected with vehicle exhibited anxiety-like behavior (Van Sickle et al., 2004) , that is, there was a significant reduction in the percentage of time spent on open arms ( Fig. 2a ; FZP/VEH: 16.0 ± 1.6%, n = 9) relative to controls (CON/VEH: 26.9 ± 1.3%, n = 10; P < 0.05). Prior GYKI-52466 injection completely prevented the reduction in time spent on open arms and thus the behavioral expression of anxiety (CON/VEH/GYKI: 29.6 ± 2.3%, n = 9; FZP/GYKI: 26.9 ± 2.1%, n = 15; P > 0.05). AMPAR currents were elevated (B30%) in neurons from the same subset of rats in which whole-cell currents could also be recorded ( Fig. 2b ; CON/VEH: 8.7 ± 0.1 pA, n = 5; FZP/VEH: 11.1 ± 0.5 pA, n = 6; P < 0.05). This significant current elevation was also eliminated by prior GYKI-52466 injection (CON/GYKI: 9.7 ± 0.5 pA, n = 6; FZP/GYKI: 9.1 ± 0.4 pA, n = 6). No differences were observed in RMP (CON/VEH, -62.3 ± 1.0 mV; FZP/VEH, -60.8 ± 1.9 mV; CON/GYKI, -61.6 ± 1.5 mV; FZP/GYKI, -60.9 ± 1.4 mV; P > 0.05), mEPSC decay (CON/VEH, 20.6 ± 2.1 ms; FZP/VEH, 20.8 ± 2.0 ms; CON/GYKI, 17.4 ± 2.7 ms; FZP/GYKI, 19.3 ± 3.0 ms; P > 0.05) or in the frequency (CON/VEH, 0.26 ± 0.11 Hz;
FZP/VEH, 0.31 ± 0.19 Hz; CON/GYKI, 0.27 ± 0.12 Hz; FZP/GYKI, 0.28 ± 0.06 Hz; P > 0.05) of AMPAR-mediated events between control and FZPwithdrawn rats that received vehicle vs. GYKI-52466 injection. The ability of GYKI-52466 to avert the increased AMPAR-medicated current in 1-day FZP-withdrawn rats also prevented AMPAR overactivity 2 days after FZP withdrawal. This observation suggests that enhanced AMPA function early during the FZP withdrawal phase may be required to initiate sustained AMPAR overactivity, as reported by Steppuhn and Turski (1993) .
As AMPAR functional changes appeared earlier after drug withdrawal than alterations in NMDAR function (Van Sickle et al., 2004) , a critical question was whether the reduction in evoked NMDAR-mediated currents was secondary to increases in AMPAR-mediated currents. We thus evaluated NMDAR-mediated eEPSCs in hippocampal slices from the same group of 2-day FZP-withdrawn rats in which AMPAR mEPSCS were recorded after 0-day GYKI-52466 or vehicle injection and 1-day elevated plusmaze testing. In the presence of AMPA, GABA A R and GABA B R antagonists, inward EPSCs were evoked in neurons voltage-clamped from -80 to + 40 mV. Representative inward NMDAR eEPSC traces at V H = -20 mV from control or FZP-withdrawn rats which received vehicle or GYKI-52466 injection immediately after drug withdrawal are shown in Fig. 2c . As reported previously (Van Sickle et al., 2004) , the NMDA-mediated eEPSC amplitude in CA1 neurons from vehicle-injected 2-day FZP-withdrawn rats was significantly reduced in comparison to their matched vehicle-injected control group (Fig. 2d . V H = -20 mV: CON/VEH, -199.9 ± 24.6 pA, n = 7; FZP/VEH, -104.9 ± 9.6 pA, n = 8; P < 0.05; V H = + 40 mV: CON/VEH: 250.9 ± 43.9 pA, n = 7; FZP/VEH: 97.9 ± 21.9 pA, n = 8; P < 0.05). Prior systemic GYKI-52466 injection had no effect on NMDARmediated currents in neurons from control rats ( Fig. 2d . V H = -20 mV: CON/GYKI: -159.3 ± 20.5 pA, n = 6; V H = + 40 mV: CON/GYKI: 274.6 ± 69.0 pA, n = 6). However, in neurons from 2-day FZP-withdrawn rats injected with GYKI-52466 immediately after FZP withdrawal, unlike in those injected with vehicle, eEPSC amplitudes were equivalent to those observed in neurons from control rats at both negative and positive holding potentials ( Fig. 2d ; V H = -20 mV: FZP/GYKI, -159.2 ± 19.4 pA, n = 7; at V H = + 40 mV: FZP/GYKI, 189.3 ± 31.9, n = 7; NS). Thus, GYKI-52466 injection immediately after FZP withdrawal not only reversed both Tween-20 (0.5 ml/kg, intraperitoneally) vehicle was given to rats immediately after the end of oral administration of FZP. Rats were tested 1 day later in the elevated plus-maze, followed 30 min later by hippocampal slice preparation for electrophysiological recording. AMPA receptor plasticity and withdrawal anxiety Xiang and Tietz 451 anxiety in 1-day FZP-withdrawn rats and AMPAR upregulation in (1-day and) 2-day FZP-withdrawn rats, but also reversed downregulation of NMDAR function 2 days after FZP withdrawal. This finding suggested that the reduction in NMDAR function might play a negative feedback role to prevent expression of CA1 neuron hyperexcitability and thus anxiety-like behavior.
MK-801 failed to prevent anxiety-like behavior and upregulation of AMPAR function
Using a similar pharmacological strategy we evaluated whether, as with some forms activity-dependent plasticity, antagonism of the NMDAR-dependent signaling pathway during FZP withdrawal is required for the enhancement of AMPAR mEPSCs observed. We injected MK-801 immediately after FZP withdrawal and rats were tested in the elevated plus-maze on day 1 of withdrawal followed 1 day later by hippocampal slice preparation.
As shown in Fig. 3a , and as observed following injection of the other antagonist vehicles ( Fig. 1a and 2a ), saline injection had no effect on the appearance of withdrawal anxiety measured as a decreased percentage of time spent on open arms in 1-day FZP-withdrawn rats in comparison to control rats (CON/VEH: 35.4 ± 2.6%, n = 5; FZP/VEH: 24.0 ± 1.7%, n = 5; P < 0.05). Likewise, pA GYKI-52466 injection at the onset of withdrawal averts the appearance of anxiety-like behavior in 1-day FZP-withdrawn rats and the increased AMPAR-mediated mEPSC amplitude and reduced NMDAR-mediated eEPSC amplitude in the same, 2-day withdrawn rats. Rats were given a single injection of GYKI-52466 (0.5 mg/kg, intraperitoneally) or vehicle (0.5 ml/kg, intraperitoneally) immediately after removal of FZP from the drinking water. Rats were tested 1 day after injection in the elevated plus-maze, followed by hippocampal slice preparation for electrophysiological recording 2 days after injection. (a) Open-arm time on an elevated plus-maze test, expressed as a percentage of total time, 1 day after vehicle or GYKI-52466 injection. One-day FZP-withdrawn rats (white bars, n = 9) injected with vehicle showed evidence of anxiety-like behavior, measured as a significant reduction (P < 0.05) in the percentage of open-arm time compared with control rats (black bar, n = 10). GYKI-52466 injection blocked the appearance of anxiety, in 1-day FZP-withdrawn rats (white bar, n = 15) compared with control rats (black bar, n = 9). (b) Two days after FZP withdrawal, the rats tested in the plus-maze the previous day were killed and AMPAR mEPSCs (V H = -80 mV) were recorded for 5 min in hippocampal CA1 neurons from the both vehicle-injected and GYKI-injected control rats (black bars, n = 6) or 2-day FZP-withdrawn rats (white bars, n = 6). Prior GYKI-52466 injection (control rats, black bar, n = 6; FZP rats, white bar, n = 6) blocked AMPAR-mediated current. (c) Representative whole-cell NMDAR current (V H = -20 mV) traces evoked by electrical stimulation (0.3-0.4 mA) of the Schaffer collateral pathway. (d) Averaged current-voltage (I-V) curves of peak NMDAR eEPSC amplitude (V H = -80 to + 40 mV) generated in CA1 neurons from vehicle-injected FZPwithdrawn rats (closed circles, n = 8) in comparison to neurons from vehicle-injected control rats (open circles, n = 7). Prior GYKI-52466 injection reversed the reduction in NMDAR eEPSC amplitude in neurons from FZP-withdrawn rats (open squares, n = 7), and was without effect on neurons from control rats (closed squares, n = 6, P < 0.05). AMPAR, a-amino-3-hydroxy-5-methylisoxasole-4-propionic acid; eEPSC, evoked excitatory postsynaptic current; mEPSC, miniature excitatory postsynaptic current.
prior MK-801 injection had no effect to modify anxietylike behavior in the plus-maze (control/MK-801: 36.3 ± 2.9%, n = 7; FZP/MK-801: 22.8 ± 2.7% n = 6; P < 0.05). As in other studies of AMPAR mEPSCs in CA1 neurons from the same rats (Fig. 3b ), there were no differences in RMP (CON/VEH: -59.4 ± 0.7 mV, FZP/VEH: -59.9 ± 0.8 mV; CON/MK-801: -59.4 ± 1.3 mV, FZP/MK-801: 9.1 ± 0.4 mV. NS), current decay (CON/VEH: 17.8 ± 3.5 ms; FZP/VEH: 17.8 ± 1.5 ms; CON/MK-801: 17.6 ± 3.1 ms; FZP/MK-801: 18.3 ± 2.9 ms. NS) or in mEPSC frequency (CON/VEH: 0.40 ± 0.25 Hz; FZP/VEH: 0.38 ± 0.56 Hz; CON/MK-801: 0.28 ± 0.12 Hz; FZP/MK-801: 0.39 ± 0.28 Hz. NS) between control and FZP-withdrawn rats. As in other FZP-withdrawn groups (Figs 1 and 2) , there was, however, a significant increase in peak mEPSC amplitude after FZP withdrawal in comparison to controls (CON/VEH: 8.7 ± 0.3 pA, n = 5; FZP/VEH: 10.7 ± 0.5 pA, n = 9; P < 0.05). Prior MK-801 injection also had no effect on control mEPSC amplitude. Furthermore, AMPAR mEPSC amplitude in CA1 neurons from FZP-withdrawn rats remained increased (CON/MK801: 8.5 ± 0.5 pA, n = 7; FZP/MK801: 11.1 ± 0.5 pA, n = 9; P < 0.05). This finding suggests that, in comparison to other forms of activity-dependent synaptic A single injection of the noncompetitive NMDAR antagonist, MK-801 (0.25 mg/kg, intraperitoneally) or saline (1 ml/kg, intraperitoneally) was given to rats immediately after FZP-withdrawal. Rats were tested 1 day after injection in the elevated plus-maze, followed by hippocampal slice preparation for electrophysiological recording. (a) Average AMPAR mEPSC amplitude (V H = -80 mV) in CA1 neurons from control (black bars) or 1-day FZPwithdrawn (white bars) rats. Neither vehicle (CON, n = 5; FZP rat, n = 9) nor MK-801 injection (CON, n = 7; FZP, n = 9) had an effect on upregulation of AMPAR mEPSC amplitude. (b) Open-arm time on an elevated plus-maze, expressed as a percentage of total time, after vehicle or MK-801 injection. 1-day FZP-withdrawn rats (white bars, n = 5), but not control rats (black bars, n = 5), injected with vehicle showed anxiety-like behavior. MK-801 injection had no effect on the appearance of anxiety, measured as a AMPA receptor plasticity and withdrawal anxiety Xiang and Tietz 453 plasticity, NMDAR-dependent signaling may not be required for the increased AMPAR-mediated glutamatergic strength during FZP withdrawal.
We also investigated the effect of MK-801 on the correlation between AMPAR mEPSC amplitude and the percentage of time rats spent on open arms of the plus maze. A positive correlation was observed (R 2 = 0.29, P < 0.05) between AMPAR-mediated mEPSC amplitude and percentage open-arm time (Fig. 3c ) in vehicle-injected FZP-withdrawn neurons, indicating a strong correlation between AMPAR function and FZP withdrawal anxiety, as shown in Fig. 1b . Prior systemic MK-801 injection also failed to modify this significant positive correlation (R 2 = 0.74, P < 0.001, Fig. 3d ). These findings further support the lack of involvement of NMDARmediated Ca 2+ influx function in initiating the enhancement of CA1 neuron AMPAR-mediated currents during FZP withdrawal and the associated behavioral expression of anxiety. 
Percentage of open arm time
Effects of systemic nimodipine injection on AMPAR-mediated mEPSCs in hippocampal CA1 neurons and anxiety-like behavior during FZP withdrawal. Rats injected with the L-type voltage-gated calcium receptor antagonist, nimodipine (10 mg/kg, intraperitoneally) immediately after FZP withdrawal were compared with those after vehicle injection (0.5% Tween-80, 2 ml/kg). The elevated plus-maze test was performed 1 day after nimodipine injection, followed 30 min later by hippocampal slice preparation and electrophysiological recording after the same protocol. (a) Openarm time in the elevated plus-maze test in 1-day FZP-withdrawn rats, 1 day after vehicle or nimodipine injection. FZP-withdrawn rats (white bars, n = 9) injected with vehicle showed evidence of anxiety-like behavior, measured as a Nimodipine reverses upregulation of AMPAR function and prevents anxiety-like behavior during flurazepam withdrawal L-Type VGCCs have been shown to be involved in mediating withdrawal signs to a variety of selective and nonselective CNS depressants including morphine, ethanol, the barbiturates and the benzodiazepines (Whittington and Little, 1993; Pourmotabbed et al., 1998; Rabbani and Little, 1999) as well as in several forms of activity-dependent plasticity (Morgan and Teyler, 1999; Borroni et al., 2000; Shinnick-Gallagher et al., 2003) . Therefore, we investigated the possible role of L-type VGCC activation to modulate the increased glutamatergic strength reflected in the enhanced AM-PAR-mediated mEPSC amplitude during FZP withdrawal. Thus, we systemically injected rats with nimodipine, a selective L-type VGCC antagonist, immediately after removal of FZP from the drinking water. Rats were then tested in elevated plus-maze 1 day later followed by hippocampal slice preparation and recording of AMPAR-mediated mEPSCs. Figure 4a shows that vehicle injection again had no effect on anxiety-like behavior in this group of 1-day FZPwithdrawn rats compared with control rats (CON/VEH: 33.3 ± 2.9%, n = 8; FZP/VEH: 18.9 ± 2.8%, n = 8; CON/NIMO: 31.4 ± 2.6%, n = 7; FZP/NIMO: 32.9 ± 2.8%, n = 9; P < 0.05). Moreover, prior vehicle injection again had no effect on basal AMPAR mEPSC amplitude in control neurons or their enhancement during FZP withdrawal (CON/VEH: 8.0 ± 1.4 pA, n = 8; FZP/VEH: 11.2 ± 1.9 pA, n = 8; P < 0.05). After nimodipine injection at the onset of withdrawal, the mean AMPAR mEPSC amplitude, however, returned to control levels in neurons from 2-day FZP-withdrawn rats (CON/NIMO: 31.4± 2.6%, n = 7; FZP/NIMO: 32.9 ± 2.8%, n = 9; NS). No differences were observed in RMP (CON/VEH: -61.8 ±1.9 mV; FZP/VEH: -62.0 ± 1.7 mV; CON/NIMO: -59.4 ± 1.2 mV; FZP/NIMO: -59.0 ± 1.9 mV; NS), current decay (CON/VEH: 17.6 ± 3.1 ms; FZP/VEH: 14.6 ±1.2 ms; CON/NIMO: 15.1 ± 0.8 ms; FZP/NIMO: 18.3 ±2.8 ms; NS) or in mEPSC frequency (CON/VEH: 0.23 ± 0.03 Hz; FZP/VEH: 0.34 ± 0.06 Hz; CON/NIMO: 0.27 ± 0.06 Hz; FZP/NIMO: 0.27 ± 0.04 Hz; NS) in neurons from control vs. FZP-withdrawn rats.
The same electrophysiological and behavioral measures were also used to investigate the effect of systemic nimodipine or vehicle injection on the relationship between AMPAR mEPSC amplitude and anxiety-like behavior. As in GYKI-52466 and MK-801 studies (Figs 1  and 3) , there was a positive correlation (R 2 = 0.48, P < 0.005) between AMPAR-mediated mEPSC amplitude and percentage open-arm time (Fig. 4c ) in FZPwithdrawn rats, indicating an analogous, strong correlation between AMPAR function and FZP withdrawal anxiety in these additional groups of vehicle-injected rats. Prior systemic nimodipine injection eliminated the significant positive relationship among the electrophysiological and behavioral measures across experimental groups (R 2 = 0.20, P = 0.08, Fig. 4d ). Together, these findings suggest that L-type VGCC-dependent Ca 2+ signaling may be required for the enhancement of AMPAR function and the associated anxiety during FZP withdrawal.
Nimodipine concentration-response
To evaluate whether systemic nimodipine injection may have a direct ability to modify AMPAR activity, the concentration-response profile for the effect of nimodipine on AMPAR-mediated mEPSC characteristics was evaluated. mEPSCs were recorded for 5 min without nimodipine during the baseline hippocampal slice-recording period. Nimodipine was then superfused in increasing concentrations ranging from 0.1 to 100 mmol/l. Average AMPAR mEPSC amplitude (V H = -80 mV) in CA1 neurons during vehicle (close circles) or nimodipine (open circles) superfusion was compared.
As shown in Fig. 5 , neither nimodipine (n = 4 cells) nor vehicle (n = 3 cells) had any effect on mEPSC amplitude (P > 0.05) at any concentration evaluated, as represented by the highest nimodipine concentration (100 mmol/l) tested (VEH: 9.1 ± 0.3 pA; NIMO: 8.7 ± 0.4 pA; NS). Moreover, no significant changes (P > 0.05) in mEPSC rise time (VEH: 3.8 ± 0.5 ms; NIMO: 3.6 ± 0.3 ms), AMPA receptor plasticity and withdrawal anxiety Xiang and Tietz 455 decay (VEH: 23.4 ± 6.5 ms; NIMO: 20.8 ± 1.4 ms) or frequency (VEH: 0.30 ± 0.07 Hz; NIMO: 0.34 ± 0.06 Hz) were observed during 100-mmol/l nimodipine superfusion.
Discussion
We previously reported that transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal anxiety (Van Sickle et al., 2004) . The goal of the present studies was to provide further support for the relationship between hippocampal CA1 neuron AMPAR-mediated excitation and the possible neurophysiological mechanisms associated with the behavioral expression of withdrawal anxiety after chronic benzodiazepine treatment. In this study, there was a positive correlation between upregulation of AMPARmediated function and anxiety-like behavior in 1-day FZP-withdrawn rats (Fig. 1a) . Antagonism of AMPAR activation by GYKI-52466 immediately after cessation of FZP treatment prevented both the subsequent AMPAR functional upregulation in CA1 neurons and FZP withdrawal anxiety in rats, and the correlation between them ( Fig. 1b and Van Sickle et al., 2004) . Furthermore, prior GYKI-52466 injection prevented AMPAR upregulation in 2-day FZP-withdrawn rats, as well as downregulation of NMDAR function (Fig. 2) . Using a similar strategy, we evaluated the actions of the NMDAR antagonist, MK-801, and the L-type VGCC antagonist, nimodipine, systemically injected at the onset of withdrawal to modify AMPAR plasticity. MK-801 failed to prevent enhancement of AMPAR currents and the correlated anxiety in 1-day FZP-withdrawn rats (Fig. 3) , whereas nimodipine reversed both the enhancement of AMPAR function and the expression of anxiety, and their correlation (Fig. 4) . Nimodipine had no direct effect on mEPSCs (Fig. 5) , supporting the likelihood that its ability to reverse the withdrawal-associated increase in AMPAR function was through blockade of L-type VGCCs.
The neurophysiological mechanisms underlying the behavioral changes occurring during benzodiazepine withdrawal are presently not well defined. Numerous studies support an important role for non-NMDAR glutamatergic mechanisms in drug dependence and addiction. Increased glutamatergic strength in mesolimbic reward pathways has been implicated in addictive behaviors (Tzschentke and Schmidt, 2003; Nestler, 2005) and evidence supports a role for enhanced hippocampal glutamatergic plasticity underlying dependence on ethanol (Molleman and Little, 1995; Sanchis-Segura et al., 2006) and morphine (Vekovischeva et al., 2001; Zhong et al., 2006) . Likewise, there is growing evidence of neuroadaptive changes in the glutamatergic system associated with benzodiazepine withdrawal (Stephens, 1995; Izzo et al., 2001; Allison and Pratt, 2003; Van Sickle et al., 2004; Song et al., 2007) . We previously reported that during FZP withdrawal, anxiety-like behavior appears in rats concomitant with increased hippocampal CA1 neuron hyperexcitability reflected in an increased frequency of extracellular spiking during 4aminopyridine superfusion, increased AMPAR-mediated mEPSC amplitude, localized upregulation of AMPAR ligand binding and protein expression and insertion of GluR1-containing AMPARs Van Sickle et al., 2004; Song et al., 2007) . This study further supports the strong link between CA1 neuron AMPAR plasticity in vitro and withdrawal anxiety in vivo (Fig. 1a) , paralleling the rapid elimination of FZP and its metabolites in the rat hippocampus (Lau et al., 1987; Xie and Tietz, 1992) . Systemic GYKI-52466 injection at the onset of this period abolished this correlation (Fig. 1b) by averting both the increased AMPAR mEPSC amplitude in vitro and FZP withdrawal anxiety in vivo, confirming a contributory role for hippocampal CA1 neuron AMPARmediated excitation in mediating withdrawal symptoms. Thus, activation of CA1 neuron AMPARs was required for inducing withdrawal symptoms. This support the observations of Steppuhn and Turski (1993) , who found that administration of GYKI-52466 during the 'silent' phase (days 1-3 of withdrawal, during which diazepamdependent mice were symptom-free) would prevent the subsequent development of withdrawal signs in the 'active' phase (days 4-21 of withdrawal, during which mice displayed classic benzodiazepine withdrawal signs). Consequently, this finding considerably strengthens the hypothesis that AMPAR-mediated hyperexcitability in hippocampal CA1 neurons is an important part of a functional anatomic circuit (Millan, 2003) that contributes to the FZP withdrawal anxiety in rats.
Regulation of NMDAR in a variety of brain areas including hippocampus has also been implicated in the development of tolerance to and dependence on a variety of drugs of abuse. Although the synaptic strength of non-NMDARs is typically increased in relation to dependence on CNS depressants (Molleman and Little, 1995; Jang et al., 2000; Vekovischeva et al., 2001; Zhong et al., 2006) , the effects on NMDARs, however, are less uniform (Whittington et al., 1995; Jang et al., 1998; Van Sickle et al., 2004) . On the basis of prior observation that AMPAR functional upregulation preceded NMDAR functional downregulation (Van Sickle et al., 2004) , the observation that downregulation of NMDARs in 2-day FZP-withdrawn rats was also averted by prior AMPAR antagonist injection suggested that downregulation of CA1 neuron NMDAR-mediated function may be secondary to enhanced AMPAR function ( Fig. 2c and d) . Moreover, these findings suggest that NMDAR regulation may play a compensatory, feedback role to prevent CA1 neuron hyperexcitability, thus dampening hippocampal output activity and preventing benzodiazepine-induced withdrawal anxiety. These studies support a neuroadaptive mechanism by which the imbalance in excitatory glutmatergic receptors during benzodiazepine withdrawal is initially AMPAR-dependent and is subsequently counterbalanced by downregulation of CA1 neuron NMDAR function, represented by a reduction in both NMDAR-mediated eEPSC amplitude (Fig. 2 , Van Sickle et al., 2004) and the levels of N-methyl-D-aspartate receptor subunit 2B (NR2B) mRNA and protein in the CA1 region . Similarly, in previously fear-conditioned rats, a model of cue-induced anxiety in which increased glutamatergic strength is reported in lateral amygdala pyramidal neurons, downregulation of NMDA-mediated synaptic strength was indicated by a 3-4-fold shift in lateral amygdala neuron NMDA potency concomitant with a decreased sensitivity of NMDA currents to the NR2B-subunit selective antagonist, ifenprodil. In fear-conditioned rats, this effect was suggested to protect against NMDAR recruitment during induction and consolidation of fear memories . It will be of significant interest to determine whether NMDAR subunit composition is altered in FZP-withdrawn rats, specifically a dynamic shift in the NR2B to NR2A subunit ratio at CA1 synapses Perez-Otano and Ehlers, 2005) . Although the role of NMDARs in the expression of fear-induced anxiety is still controversial Rodrigues et al., 2004) , taken together with findings in FZP-withdrawn CA1 neurons these data suggest the possibility that downregulation of NMDARs, probably the regulation of NR2B-containing receptors, may be a common negative feedback mechanism to avert expression of anxiety-like behavior associated with increased glutamatergic strength in brain nuclei subserving anxiety.
Neuronal plasticity is defined as a use-dependent increase in the efficiency of synaptic transmission. Examples include the phenomenon of long-term potentiation (LTP), fear-conditioning and repeated drug administration (Malenka, 2003; Rodrigues et al., 2004; Nestler, 2005) . Activity-dependent changes in synaptic function are primarily the consequence of an intracellular calcium-dependent biochemical cascade and involve changes in synaptic AMPAR number and/or function (Song and Huganir, 2002; Boehm and Malinow, 2005) . Regulation of AMPAR recruitment by NMDAR-dependent calcium signaling has been well described in activity-dependent plasticity models (Shi et al., 1999; Malinow, 2003) . Systemic administration of the NMDAR antagonist MK-801, previously reported to restore downregulation of NMDAR function in CA1 neurons from flurazepam-withdrawn rats (Van Sickle et al., 2004) , however, failed to reverse the induction of CA1 neuron AMPAR upregulation and the concomitant anxiety in FZP-withdrawn rats ( Fig. 3a and b) or the correlation between these measures ( Fig. 3c and d) . This suggests that an NMDAR-independent signaling pathway may underlie AMPAR upregulation associated with FZP withdrawal anxiety.
L-VGCCs have also been reported to play role in each of the above-mentioned activity-dependent models of synaptic plasticity (Morgan and Teyler, 1999; Borroni et al., 2000; Rajadhyksha and Kosofsky, 2005) . Indeed, a role for L-VGCC-mediated Ca 2+ influx in dependence on other CNS depressants such as ethanol, barbiturates and morphine has been reported (Whittington and Little, 1993; Pourmotabbed et al., 1998; Rabbani and Little, 1999) . L-Type calcium channel blockers such as nimodipine, nifedipine and verapamil were reported to block a variety of lorazepam-withdrawal signs including hyperkinesia, hyperthermia, hyperaggression and audiogenic seizures (Chugh et al., 1992; Gupta et al., 1996; Ganouni et al., 2004) . Nitrendipine dose-dependently decreased seizures precipitated by the benzodiazepine receptor partial agonist FG7142 (Dolin et al., 1990) . The finding that injection of the L-type VGCC antagonist, nimodipine, reversed the upregulation of CA1 neuron AMPAR function in 1-day FZP withdrawn rats as well as withdrawal anxiety ( Fig. 4a and b ) raises the possibility that calcium influx through L-type VGCCs may activate diverse intracellular messengers or transcription factors to increase glutamatergic strength during benzodiazepine withdrawal. In fact, it has been well described that, in ethanol withdrawal and following psychostimulant administration, activation of L-type VGCCs can result in the influx of intracellular calcium and downstream activation of Ca 2+ /CaM-activated kinase and phosphatase pathways, eventually involving CREB-induced gene expression, also important to neuronal and experience-dependent plasticity (Groth et al., 2003; Nestler, 2005; Rajadhyksha and Kosofsky, 2005; Xia and Storm, 2005) .
Dihydropyridine (DHPs) are highly selective calcium channel blockers. Nimodipine binds to rat, guinea pig and human brain membranes with high affinity (less than 1 nmol/l) and concentrations as low as 10-20 nmol/l were reported to block inward Ca 2+ currents (Scriabine et al., 1989) . DHPs can block a variety of non-L-type calcium channels, including GABA A R, nicotinic acetylcholine receptors and 5-HT3A receptors (Hargreaves et al., 1996; Houlihan et al., 2000; Das et al., 2004) at IC50s in the micromolar to millimolar range. Considering the much higher affinity and efficacy of nimodipine on L-type VGCCs than other channels (nmol/l vs. mmol/l to mmol/l), impairment of L-type VGCC-mediated signaling pathways is the most reasonable explanation for nimodipine, averting the increase in CA1 neuron mEPSC current amplitude and FZP withdrawal anxiety. Indeed, Fig. 5 showed that nimodipine in the mmol/l concentration range had no direct effects on AMPAR-mediated mEPSCs, supporting the latter explanation. Furthermore, it has been suggested that in the brain the density of neuronal L-type Ca 2+ channels is significantly higher than that of vascular ones (Ricci et al., 2002) . This might explain the more pronounced neuronal as opposed to vascular effects after pharmacological manipulation of cerebral Ca 2+ channels.
Further studies are needed to determine the cellular mechanisms by which L-type VGCCs are activated during FZP withdrawal. Currently, we favor two hypotheses. First, a few studies have shown an increased concentration of intracellular calcium through L-type VGCCs after prolonged GABA A R activation that leads to bicarbonatedriven Clentry and Claccumulation, and eventually promotes cell depolarization (Reichling et al., 1994; Chavas et al., 2004; Marty and Liano, 2006) . As a consequence of prolonged GABA A R activation during FZP administration, numerous time-dependent changes occur at the GABA A R, some of which influence CA1 neuron hyperexcitability (Van Sickle et al., 2004) including a bicarbonate-driven Claccumulation reflected in a shift in the Clreversal potential and the appearance of a bicuculline-sensitive depolarizing potential (Zeng et al., 1995; Tietz, 1997, 2000) . Second, as this flurazepam treatment and other common diazepam treatments (Gallager et al., 1985) result in brain levels of benzodiazepine metabolites in the low micromolar range (0.6 mmol/l in diazepam equivalents), benzodiazepines might also directly modulate the activity of L-VGCCs, as shown by their ability to directly inhibit L-VGCC-mediated Ca 2+ flux (Taft and DeLorenzo, 1984; Gershon, 1992; Reuveny et al., 1993; Ishizawa et al., 1997) . The modulation of L-type VGCC activity during benzodiazepine withdrawal is currently under investigation (Xiang et al., 2006) .
On the basis of evidence to date, a model of the proposed cellular mechanisms underlying benzodiazepine withdrawal hyperexcitability in hippocampal CA1 neurons is shown in Fig. 6 , which provides a framework for the hypotheses that direct our ongoing mechanistic studies. L-type VGCCs could be activated by the GABA A Rmediated membrane depolarization (Zeng et al., 1995) and/or channel activity enhanced by direct benzodiazepine effects during prolonged drug administration. Increased L-type VGCC-mediated Ca 2+ entry and activation of downstream Ca 2+ -mediated signaling cascades, including activation of well-described kinase and phosphatase pathways (Rajadhyksha and Kosofsky, 2005) , could contribute to AMPAR plasticity, likely by increasing GluR1-containing AMPAR channel number, modifying AMPAR subunit composition Song et al., 2007) and/or subunit phosphorylation similar to other models of activity-driven synaptic plasticity (Malenka, 2003; Boehm and Malinow, 2005) . Enhanced AMPAR function could further promote CA1 neuron membrane depolarization and serve as a major driving force contributing to the observed CA1 neuron hyperexcitability and benzodiazepine withdrawal anxiety (Van Sickle et al., 2004). In addition, enhanced AMPAR activation would lead to NMDAR activation and subsequent downregulation, possibly of NR2B-containing NMDARs , which likely plays a protective role to prevent AMPAR-driven overexcitation in CA1 neurons, and in anxiety circuits in other areas of the brain Rodrigues et al., 2004) .
In summary, this study provides evidence that enhanced CA1 neuron AMPAR activity contributes to benzodiazepine withdrawal anxiety, which leads to a localized downregulation of NMDAR activity. Further studies suggest that enhanced AMPA-mediated glutamatergic strength may be elicited through an L-type VGCC, rather than an NMDAR-dependent signaling pathway. Given that many drugs of abuse induce similar manifestations of drug withdrawal, L-type VGCC-mediated calcium signaling and glutamate receptor plasticity may constitute a common neurophysiological mechanism for the expression of withdrawal anxiety and drug dependence. L-VGCC Proposed cellular mechanisms in hippocampal CA1 neurons associated with FZP-withdrawal anxiety. Chronic FZP treatment results in prolonged GABA A receptor activation and bicarbonate-driven Clentry and accumulation that leads to GABA A receptor-mediated depolarization. This depolarization may activate L-type VGCCs and increase Ca 2 + entry. A downstream Ca 2 + -mediated signaling cascade could facilitate an increase in AMPAR-mediated glutamatergic strength via an increase in AMPAR channel number related to an increase in exocytosis or gene expression, or through an alteration in AMPAR subunit composition and/or phosphorylation state, similar to other activity-driven synaptic plasticity phenomena. Enhanced AMPAR function would further promote CA1 neuron membrane depolarization and serve as the major driving force contributing to CA1 neuron hyperexcitability, thus modulation of hippocampal output and the expression of anxiety-like behavior. Enhanced AMPAR-mediated function will also lead to NMDAR activation. The subsequent downregulation of NMDAR function may serve as a negative feedback mechanism to regulate expression of benzodiazepine withdrawal anxiety in response to the increased AMPAR-mediated glutamatergic strength.
